Effects of polymorphisms in TNFA and TNFR2 on the outcome of 462 cases of unrelated bone marrow transplantation (uBMT) were studied retrospectively. Four alleles of TNFA (U01-U04) distinguished by polymorphism in the upstream region, −1031 (T/C), −863 (C/A) and −857 (C/T), and two alleles of TNFR2 (196M/196R) distinguished by polymorphism at codon 196 were determined. Transplantation involving TNFA-U02-and/or U03-positive donors and/or recipients resulted in a higher incidence of graft-versus-host disease (GVHD) of grade III-IV (P Ͻ 0.05 for donor type, P Ͻ 0.01 for recipient type) and a lower relapse rate than that involving TNFA-U01 homozygous recipients and/or donors (P Ͻ 0.025 for donor type, P Ͻ 0.01 for recipient type). These results include the HLA mismatching effect due to linkage disequilibirium of TNFA with HLA loci. However, the effects were also observed in HLA-A, -B and -DRB1 allele-matched transplantation. Transplantation from TNFR2-196R-positive donors exhibited a higher incidence of severe GVHD (P Ͻ 0.05) and tendency for a lower relapse rate than that from TNFR2-196M homozygous donors. TNFR2-196R of recipient origin had no effect on GVHD but increased the relapse rate (P Ͻ 0.025). These results suggest that TNFA and TNFR2 typings are helpful for predicting uBMT outcome and for preventing severe complications at an early stage.
match. On the other hand, there are some cases in which HLA mismatch is permitted. Therefore, it is likely that the onset of GVHD depends not only on antigen mismatching but also on the difference among individuals in terms of immunological sensitivity.
TNF␣ is a multifunctional proinflammatory cytokine which is produced mainly by monocytes and macrophages, and upregulates endothelial adhesion molecules, as well as MHC class I and class II molecules. 1 It has been reported that increased serum TNF␣ levels during pretransplant conditioning are associated with the severity of acute GVHD 2, 3 and a lower relapse rate. 3 Furthermore, neutralization of TNF␣ 4, 5 has been reported to reduce complications after BMT.
Polymorphisms in the promoter region and the upstream region of the TNFA gene are known. 6 Some of the polymorphisms are reported to be associated with a difference in TNF␣ production. Kroeger et al 7 reported that the −308A (adenine) allelic form has a two-fold greater level of transcription than the −308G (guanine) form. The high TNF␣ production genotype is significantly associated with acute rejections of heart 8 and renal transplants, 9 and severity of acute GVHD after BMT. 10 In the Japanese population, however, the frequency of the substitution at position −308 is very low, and other polymorphisms, −1031 (T/C), −863 (C/A) and −857 (C/T), affect TNF␣ production activity. 11 Two distinct TNF receptors, TNFR1 (p55) and TNFR2 (p75), have been identified. TNFR2 has a polymorphism at codon 196, 196M/R (methionine/arginine), and the polymorphism is associated with SLE. 12 In this study, the upstream region of TNFA and codon 196 of TNFR2 were analyzed and the effects on the outcome of unrelated bone marrow transplantation (uBMT) were studied.
Materials and methods

Samples
Donor and recipient pairs (462 pairs) who underwent unrelated bone marrow transplantation performed by The Japan Marrow Donor Program between February 1994 and March 1996 were examined (Table 1) . Genomic DNA was prepared from peripheral blood using a DNA Blood kit (Qiagen, Hilden, Germany). The HLA-A, -B, -DRB1 alleles of the samples were determined by the methods described previously. 13 
Analysis of TNFA polymorphism
The upstream region of TNFA (from −1292 to −822) was amplified using primers described by Matsushita et al. 14 Polymorphisms in the PCR fragment were determined by the PCR-SSOP (sequence-specific oligonucleotide probe) method using six probes ( Table 2) .
Analysis of TNFR2 polymorphism
Exon 6 of TNFR2 was amplified by a method described previously. 12 The PCR conditions consisted of an initial denaturation at 94°C for 5 min, followed by 30 cycles of denaturation at 94°C for 30 s, annealing at 60°C for 30 s, and extension at 72°C for 30 s. The amplified DNA was analyzed by the PCR-SSOP method using two probes ( Table 2) . 
Statistical analyses
The incidence of acute GVHD (grade III-IV) and relapse rate were estimated using the Kaplan-Meier method, and the generalized Wilcoxon test was used to analyze the difference. Differences in patient-, disease-and transplantrelated characteristics between the subdivided groups were compared using the 2 test. The Cox proportional hazard model was applied to multivariate analysis of the effects of these characteristics on BMT outcomes.
Results
Polymorphisms of TNFA and TNFR2
TNFA alleles (U01, U02, U03 and U04) 14 were identified based on the combination of substitutions at positions −1031, −863 and −857. The frequencies of the TNFA genotype of recipients and donors were almost equal and consistent with the results for the Japanese population previously reported 14 ( Table 3 ). The most frequent allele was U01 and a homozygote for U04 was not observed. Table 4 shows the frequencies of TNFR2 genotypes and alleles. The frequencies in donors and recipients were almost the same and consistent with the results for the healthy Japanese population previously reported. 12 
Effect of TNFA polymorphism on outcome of uBMT
Higuchi et al 11 have reported that TNFA-U02 and U03-positive individuals are high TNF␣ producers compared with U01. Therefore, the outcome of unrelated bone marrow transplantation was compared between U01 homozygotes and those having U02 and/or U03. The clinical characteristics of the subdivided groups are shown in Table 5 . The characteristics were not significantly different between the subdivided groups except for 'Disease (Donor's TNFA = U01 vs U02/U03)' and 'Total body irradiation (Recipient's TNFA = U01 vs U02/U03)'. Multivariate analysis revealed that the effect of 'Disease' and 'Total body irradiation' on GVHD development are not significant (data not shown). The cumulative rate of GVHD incidence was higher in the case of transplantation involving U02 and/or U03-positive donors and/or recipients (Figure 1a,b) . However, this result included the effect of HLA mismatching, because the HLA mismatching rates of groups subdivided based on the TNFA type were significantly different (Table 6 ). To exclude the HLA mismatching effect, the TNFA type effects were reanalyzed using only HLA-A, -B, -DRB1 allele-matched cases. The same effect was observed in HLA allele-matched transplantation (Figure 1c, d) . To clarify the effect of TNFA donor type and of TNFA recipient type, transplantation to U01 homozygous recipients and transplantation from U01 homozygous donors were analyzed. U01 homozygous recipients developed GVHD at a higher incidence in the case of transplantation from U02-and/or U03-positive donors than that from U01 homozygous donors (Figure 1e ). Furthermore, in the case of transplantation from U01 homozygous donors, the incidence of GVHD in U02-and/or U03-positive recipients was higher than that in U01 homozygous recipients (Figure 1f ). Figure 2 shows the effect of TNFA polymorphism on the relapse rate. The relapse rate among recipients with transplants from U02-and/or U03-positive donors was lower than that among recipients with transplants from U01 homozygous donors (Figure 2a ). U02 and/or U03-positive recipients also exhibited a decreased relapse rate (Figure 2b ). The same effect was observed in HLA-A, -B and -DRB1 allele-matched cases (Figure 2c, d) , although the differences were not significant (P Ͻ 0.1). The characteristics of 'Disease' were significantly different between the U01 homozygous donor group and the U02-and/or U03-positive donor group (Table 5) . CML was a risk factor for relapse based on the results of the multivariate analysis. In spite of the fact that the U02-and /or U03-positive donor Bone Marrow Transplantation group includes CML recipients at a rate higher than that in the U01 homozygous group (Table 5) , the U02-and/or U03-positive group exhibited a lower relapse rate.
Effect of TNFR2 polymorphism on outcome of uBMT
The effect of TNFR2 polymorphism was compared between 196M homozygotes and those having 196R (196M/196R and 196R homozygotes), because the frequency of 196R homozygotes was low (Table 4) . Transplantation from 196R-positive donors resulted in a higher cumulative rate of GVHD incidence ( Figure 3a ) and a lower relapse rate (not significant) than that from 196R-negative donors. In comparison with the recipient type, the effects of TNFR2 polymorphism were different from those of the donor type. That is, no effect was observed on the incidence of GVHD (Figure 3b ), but the relapse rate among 196R-positive recipients was higher than that among 196R-negative recipients (Figure 3d ).
Discussion
There are some reports on polymorphisms of TNFA and the association between polymorphisms and transcription activity. 6 Although Uglialoro et al 15 pointed out that the positions of polymorphisms in the TNFA promoter were misnumbered, we used spread numbers for easy comparison with other reports. The effects of the cytokine and/or the polymorphism at position −308 on transplantation have been studied. [8] [9] [10] [16] [17] [18] [19] In our report, the effects of polymorphisms at positions −1031 (T/C), −863 (C/A) and −857 (C/T), which have been reported in the Japanese population, 11 on the outcomes of uBMT were studied. uBMT involving TNFA-U02-and/or U03-positive donors and/or recipients resulted in a higher incidence of acute GVHD of grade III-IV and a lower relapse rate. However, the U02-and/or U03-positive donor and -recipient groups include HLA-mismatched transplantation at a rate higher than in the U01 homozygous groups. Because TNFA is mapped in the HLA class III region near the class I region, TNFA and HLA genes are in linkage disequilib- rium. HLA allele mismatching is the main cause of GVHD development. 20 To distinguish the effects of HLA mismatching from those of TNFA polymorphism, the effects were analyzed using only HLA-A, -B and -DRB1 allelematched cases (Figures 1c, d and 2c, d) . U02-and/or U03-positive transplantation exhibited a higher incidence of GVHD and a lower relapse rate, even in the HLA-matched transplantation, although the differences were not significant except for the GVHD incidence by the recipient type (Figure 1d ). These results show that the TNFA genotype affects the GVHD incidence and relapse rate independent of HLA mismatching. TNF␣ upregulates adhesion molecules and HLA molecules 1 and proliferation of T cells. 21 Therefore, a higher incidence of GVHD and a lower relapse rate observed in U02-and/or U03-positive transplantation appeared to reflect a higher responsiveness of T cells with respect to high TNF␣ production, because U02-and U03-carrying cells are high TNF␣ producers. The effects of TNFA polymorphism were observed in both donor and recipient types independently. TNF␣ is mainly produced by monocytes and macrophages. As 73% of the recipients analyzed in this study were subjected to total body irradiation (TBI)-conditioning regimens (average dose: 11.6 Gy), the level of PBMC of the recipients was expected to decrease significantly 22 following TBI. However, the serum TNF␣ level was reported to increase folBone Marrow Transplantation lowing TBI and/or chemotherapy in the conditioning regimen before transplantation. TNFR2 polymorphism at codon 196 also affected the outcome of uBMT. The effects of TNFR2 of a donor type and that of a recipient type were different. TNFR2-196R of donor origin exhibited similar effects to those of TNFA-U02 and/or -U03, ie higher GVHD incidence and lower relapse rate. 196R of recipient origin, however, exhibited no effect on GVHD incidence but increased the relapse rate. Since the effector cells in GVHD are from the donor, it is acceptable that TNFR2 of the recipient type exhibited no effect on GVHD. TNFR2 promotes T cell proliferation 24, 25 and MHC class II-stimulated alloresponses. 26 However, since the T cell number of recipients decreased significantly following TBI, functions that lead to antitumor activity cannot be expected. TNF␣ increases the proliferation of leukemia cells. 27 The TNFR2 recipient type may affect the activity. Although the effect of substitution at codon 196 on the TNFR2 function is not known, our results suggest that TNFR2-196R is a high responder compared with −196M.
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TNFA and TNFR2 polymorphisms are associated with the incidence of GVHD and relapse rate in uBMT. Development of severe GVHD and relapse were not found to be related by the 2 × 2 2 analysis. Therefore, the GVHD incidence and the relapse rate are independently affected by the above-mentioned polymorphisms. Although further study is needed to clarify the mechanism of the association, our results show that genotyping of these genes is useful to determine the risk of acute GVHD development and relapse rate before transplantation.
